Emergex COVID-19 vaccine

**Emergex COVID-19 vaccine** is an investigational synthetic **peptide nanoparticle vaccine** for prevention of COVID-19, developed by **Gylden Pharma** and originally by **Emergex Vaccines**. The candidate is designed as a **T cell-priming vaccine** composed of a defined cocktail of **SARS-CoV-2 coronavirus peptides** displayed on a **gold nanoparticle carrier**, and is intended for **intradermal administration using microneedle devices**. Its proposed mechanism is to prime naive **CD8-positive T cells** and generate **virus-specific cytotoxic T lymphocytes** and tissue-resident memory T cells that eliminate infected cells rather than primarily relying on neutralizing antibodies. The program has been positioned as a potentially **variant-agnostic** COVID-19 vaccine with possible activity across SARS-CoV-2 variants and SARS-CoV-1-related epitopes, and the provided context indicates completion of **Phase 1** clinical testing in Switzerland and selection by **NIH/NIAID Project NextGen** for further evaluation.

Brand names

CoronaTcP

Other names

Emergex COVID-19 vaccine